Compositions for treating pathological calcification conditions, and methods using same
AssigneeYale University
InventorsDemetrios Braddock, Ronald Albright
Life of this patent
Estimating the term…
Abstract
The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.
Claims20
A method for treating a mammalian subject having a loss of function mutation in cluster of differentiation 73 (CD73), the method comprising:
- administering to the mammalian subject a soluble ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) fusion polypeptide, thereby treating the mammalian subject, wherein the soluble ENPP1 fusion polypeptide comprises an enzymatically active ENPP1 polypeptide, a human IgG Fc, and a linker sequence linking the enzymatically active ENPP1 polypeptide and the human IgG Fc.
A method for treating or ameliorating arterial and joint calcification disease (ACDC) in a mammalian subject, the method comprising administering to the mammalian subject a soluble ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) fusion polypeptide, thereby treating ACDC in the mammalian subject, wherein the soluble ENPP1 fusion polypeptide comprises an enzymatically active ENPP1 polypeptide, a human IgG Fc, and a linker sequence linking the enzymatically active ENPP1 polypeptide and the human IgG Fc.
Dependencies are inferred from the claim text.